GE HealthCare Technologies Inc. - Common Stock (GEHC)
76.45
+1.70 (2.27%)
NASDAQ · Last Trade: Nov 22nd, 1:01 AM EST
Detailed Quote
Previous Close
74.75
Open
74.89
Bid
76.25
Ask
77.11
Day's Range
73.35 - 77.09
52 Week Range
57.65 - 94.80
Volume
8,388,818
Market Cap
34.71B
PE Ratio (TTM)
15.80
EPS (TTM)
4.8
Dividend & Yield
0.1400 (0.18%)
1 Month Average Volume
4,252,988
Chart
About GE HealthCare Technologies Inc. - Common Stock (GEHC)
GE HealthCare Technologies Inc. is a leading global medical technology and digital solutions innovator focused on improving patient outcomes through advanced healthcare solutions. The company develops and manufactures a wide range of diagnostic imaging systems, monitoring devices, and healthcare IT services that empower healthcare providers to deliver accurate and efficient patient care. Through its commitment to innovation, GE HealthCare supports clinicians and patients by providing tools that enhance diagnostic capabilities, streamline workflows, and facilitate data-driven decision-making in an increasingly complex healthcare environment. Read More
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
GE HealthCare (Nasdaq: GEHC) announced it has entered into an agreement to acquire Intelerad, a leading medical imaging software provider for the healthcare industry, for a purchase price of $2.3 billion paid in cash. This acquisition demonstrates GE HealthCare’s continued commitment to cloud-enabled and AI-powered solutions across care settings and furthers the company’s aim to triple its offerings of cloud-enabled products by 2028.
In a pivotal shift for artificial intelligence in healthcare, researchers and developers are increasingly focusing on the reliability and diagnostic accuracy of AI methods for processing medical images, moving decisively beyond mere aesthetic quality. This re-prioritization underscores a maturing understanding of AI's critical role in clinical settings, where the stakes are inherently high, and trust [...]
GE HealthCare (Nasdaq: GEHC) today announced that Cardiovascular Associates of America (CVAUSA), the largest network of private cardiology groups in the U.S., plans to broaden its adoption of GE HealthCare’s FDA-approved cardiac positron emission tomography (PET) radiotracer Flyrcado™ (flurpiridaz F 18) injection, across approximately 25 sites following a successful pilot at Cardiovascular Medicine in Davenport, Iowa. This planned rollout marks a significant milestone for advancing PET myocardial perfusion imaging (MPI) in community cardiology settings and reflects growing confidence in Flyrcado’s role in shaping the future of cardiac imaging.
Recent breakthroughs in multimodal Artificial Intelligence (AI) are fundamentally reshaping the landscape of cancer research, ushering in an era of unprecedented precision in diagnosis and personalized treatment. By intelligently integrating diverse data types—from medical imaging and genomic profiles to clinical notes and real-world patient data—these advanced AI systems offer a holistic and nuanced understanding of [...]
GE HealthCare’s third quarter saw revenue and adjusted profit come in slightly above Wall Street’s expectations, but the market reacted negatively, reflecting concerns about margin pressures. Management pointed to strong demand across imaging and pharmaceutical diagnostics as primary drivers, with robust orders growth and new enterprise deals contributing to a healthy backlog. However, increased tariffs and a product hold in Patient Care Solutions weighed on profitability. CEO Peter Arduini noted, “We delivered robust orders growth of 6% with growth across all segments,” while CFO Jay Saccaro highlighted that tariff impacts reduced adjusted EBIT margin by 180 basis points, partially offset by volume and pricing gains.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped returns as the industry’s six-month gain of 9.8% has lagged the S&P 500’s 22.6% climb.
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 5.8% year on year to $5.14 billion. Its non-GAAP profit of $1.07 per share was 2.2% above analysts’ consensus estimates.
GE HealthCare Q3 earnings beat estimates as sales rise 6% and orders grow 6% organically, prompting a raised full-year profit outlook despite tariff costs.
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 5.8% year on year to $5.14 billion. Its non-GAAP profit of $1.07 per share was 2.2% above analysts’ consensus estimates.
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC)
will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.
NetworkNewsWire Editorial Coverage : Artificial intelligence (“AI”) is making inroads into every corner of medical technology, perhaps none more urgently than imaging. In breast cancer detection, where early diagnosis can mean the difference between life and death, AI-enhanced modalities present a chance to leap beyond the limits of mammography, tomosynthesis, and MRI. Globally, breast cancer remains one of the most common cancers in women. According to the World Health Organization (“WHO”), more than 2.3 million women were diagnosed with breast cancer in 2022, and approximately 670,000 women died from the disease globally. In the United States, the American Cancer Society (“ACS”) projects that 316,950 new invasive breast cancer cases will be diagnosed among women this year. The urgent, life-saving need for earlier and more accurate detection creates a powerful opportunity for innovation in diagnostic imaging. Amid this global challenge, companies advancing breast cancer diagnostics are entering a high-impact field. Among them, Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) ( profile ) stands out with its next-generation IzoView Breast CT Imaging System, a dedicated 3D imaging platform designed to improve detection accuracy, particularly for women with dense breast tissue. IzoView joins an elite group of companies, including Hologic Inc. (NASDAQ: HOLX), GE HealthCare Technologies Inc. (NASDAQ: GEHC), Nano-X Imaging Ltd. (NASDAQ: NNOX) and Oracle Corp. (NYSE: ORCL), that are focused on playing a….
GE HealthCare (Nasdaq: GEHC) today announced collaborations with two leading U.S. health systems—The Queen’s Health Systems in Honolulu, HI and Duke Health in Durham, NC—to help advance the development of GE HealthCare’s new AI-driven hospital operations software. Both health systems plan to contribute their frontline expertise to inform GE HealthCare’s forthcoming cloud-first Software as a Service solution that will be part of GE HealthCare’s CareIntellect family of applications. User feedback is central to GE HealthCare’s customer-driven approach to developing solutions that tackle health systems’ biggest needs and provide better, faster care to more patients. The new solution will use AI and predictive analytics to recommend actions. These features are designed to give hospital leaders the actionable insights and suggestions they need to adjust in real-time to deliver high-quality, efficient care.
GE HealthCare (Nasdaq: GEHC) today announced the launch of CareIntellect™ for Perinatal2, a cloud-first Software-as-a-Service (SaaS) application designed to deliver clear, actionable insights that help clinicians improve maternal and fetal care.3 CareIntellect for Perinatal supports clinicians by integrating information from disparate clinical sources in a single place, making it fast and easy for clinicians to monitor status, annotate clinical events, search historical data, and remotely monitor patients—with the aim of providing timely patient insights. This is the second application within GE HealthCare’s CareIntellect family of clinical and operational applications, built to help healthcare systems quickly and easily deploy and scale new applications.
